PHASE I ORAL CAPECITABINE + CISPLATIN FOR ADVANCED DIGESTIVE SYSTEM CANCERS

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这是一项口服氟嘧啶卡培他滨(希罗达)间歇给药并联合静脉注射顺铂治疗晚期消化系统癌症患者的I期研究。目标是确定剂量限制毒性、最大耐受剂量和推荐的第二阶段剂量。联合制剂之间的重大相互作用将被确定。可能的抗肿瘤效果将被确定为次要目标。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a Phase I study of oral fluoropyrimidine capecitabine (Xeloda) delivered on an intermittent scedule and combined with intravenous cisplatin in patients with advanced cancer of the digestive system. The objectives are to establish dose-limiting toxicities, maximum tolerated dose, and the recommended Phase II dose. Significant interaction between the combined agents will be determined. Possible antitumor effectiveness will be determined as a secondary objective.